The proportions of CD4+CD3+ and CD8+CD3+ T cells and CD19+ and CD5+CD19+ B cells were examined in PBMCs collected from 21 of 28 patients with HNSCC prior, during, and following combination radiotherapy (Table 1). This evidence concerns the gene CD19 and head and neck squamous cell carcinoma.